The three G-protein-coupled cannabinoid receptor subtypes currently recognized are central (CB1), peripheral (CB2), and GPR55. The majority of CB1 receptors are found at central and peripheral nerve terminals. CB2 receptors are mainly found in immune cells and non-neuronal tissues where they regulate cytokine release and cell migration. According to recent reports, the CNS may also express CB2 receptors. Non-CB1/CB2 receptors known as GPR55 show affinity for endogenous, botanical, and synthetic cannabinoids. Anandamide and 2-arachidonylglycerol are examples of endogenous ligands for cannabinoid receptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V5025 | Linoleylethanolamide | 68171-52-8 | Linoleylethanolamide is a novel and potent endocannabinoid agent that acts by binding to TRPV1 (Ki = 5.60 uM), increasing ERK phosphorylation and AP-1 dependent transcription in CB-receptor in an independent manner. |
|
V1515 | Rimonabant (SR141716) | 168273-06-1 | Rimonabant (formerly known as SR-141716; A-281; A281; SR 141716A; Acomplia; Zimulti), an anorectic antiobesity drug once used in EU but withdrawn from marketdue to serious psychiatric side effects, is a novel, potent and selective antagonist (inverse agonist) of cannabinoid CB1 receptor. |
|
V3565 | Rimonabant HCl (SR141716) | 158681-13-1 | Rimonabant (also known as SR141716, SR-141716A; A 281) is a novel, potent and selective antagonist (inverse agonist) of cannabinoid CB1 receptor with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane. |
|
V1520 | BML-190 (Indomethacin morpholinylamide; IMMA) | 2854-32-2 | BML-190 (formerly IMMA; LM-4131; BML-190; LM4131; BML190; Indomethacin morpholinylamide), is a potent and selective cannabinoid CB2 receptor inverse agonist with potential anti-inflammatory activity. |
|
V11283 | Anandamide | 94421-68-8 | Anandamide is an endocannabinoid. |
|
V26985 | Otenabant (CP-945598) | 686344-29-6 | Otenabant free base (also known as CP-945,598) is a novel, potent and highly selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, it exhibits >10,000-fold greater selectivity against human CB2 receptor. |
|
V1518 | Otenabant (CP-945598) HCl | 686347-12-6 | Otenabant HCl (also known as CP-945,598; CP 945,598; CP-945598), the hydrochloride salt of Otenabant, is a novel, potent and highly selective cannabinoid receptor CB1 antagonist with potential anti-obesity effect. |
|
V4367 | TARANABANT | 701977-09-5 | Taranabant (aslo known as MK-0364) is a novel, highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
